|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We conclude that impact of miR-493-5p on multiple pathways pertinent to genome stability cumulatively causes PARPi/platinum resistance in BRCA2 mutant carcinomas.
|
29617652 |
2018 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In patients with BRCA mutant or BRCA wild-type and LOH high platinum-sensitive ovarian carcinomas treated with rucaparib, progression-free survival was longer than in patients with BRCA wild-type LOH low carcinomas.
|
27908594 |
2017 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HGSC associated with BRCA2 but not BRCA1 mutations had significantly lower PNN compared to HGSC in non-carriers (54% vs. 70%, P=0.018).
|
27575909 |
2016 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Overall, 79% of tumors were classified as high-grade serous carcinoma (n=138), and the most common mutations in high-grade serous carcinomas were TP53 (94%), BRCA1 (25%), BRCA2 (11%), and ATM (7%).
|
27150160 |
2016 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
BRCA2 mutations were observed with a frequency of 14.3% in ampulla of Vater carcinomas.
|
27532258 |
2016 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In addition, one of the 9 active compounds, adenosine 5'-monophosphate (A5MP), and also its mimic 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) 5' phosphate (ZMP) inhibited RAD52 activity in vivo and exerted synthetic lethality against BRCA1 and BRCA2-mutated carcinomas.
|
26784987 |
2016 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We studied 102 high-grade serous carcinomas with known BRCA1 and BRCA2 genotype from the archives of the Department of Pathology at Memorial Sloan-Kettering Cancer Center.
|
24577588 |
2014 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
If true, an increased incidence of uterine papillary serous carcinomas would be expected in BRCA1 and BRCA2 mutation carriers, who are at high-risk of developing pelvic high-grade serous carcinoma.
|
23080033 |
2013 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We identified 43 high-grade ovarian serous carcinomas with known events in BRCA1 and BRCA2 included in The Cancer Genome Atlas Project.
|
23232854 |
2013 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Seven BRCA1 and one BRCA2 mutation carriers were diagnosed with primary peritoneal serous carcinoma; no peritoneal carcinomas were registered in MMR gene mutation carriers.
|
23666231 |
2013 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Using mutagenesis and a peptide aptamer approach, we pinpointed phenylalanine 79 in RAD52 DNA binding domain I (RAD52-phenylalanine 79 [F79]) as a valid target to induce synthetic lethality in BRCA1- and/or BRCA2-deficient leukemias and carcinomas without affecting normal cells and tissues.
|
23836560 |
2013 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
53BP1 message levels were significantly associated with BRCA1 message levels in wildtype and BRCA1-mutated but not BRCA2-mutated carcinomas.
|
23246380 |
2013 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, the best clinical criterion for starting with BRCA2 analysis is the presence of breast cancer diagnosed in older age (above 50), or the presence of breast cancer in conjunction with carcinomas at different sites e.g., prostate, colorectum, ovary and uterus.
|
21203900 |
2011 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In paired specimens, BRCA1 protein expression increased in 13/21 (62%) and BRCA2 protein expression increased in 15/21 (71%) of recurrent carcinomas with low or intermediate protein in the paired primary.
|
19602291 |
2009 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Although ovarian carcinomas with mutated BRCA1 or BRCA2 are sensitive to platinum compounds, such carcinomas eventually develop platinum resistance.
|
18413725 |
2008 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Since myoepithelial markers are frequently expressed in breast carcinomas with a basal-like phenotype, which are frequently occurring tumors in women with BRCA1 germline mutations, we evaluated whether CAV1 was associated with a basal-like phenotype in 509 sporadic and 47 hereditary BRCA1-/BRCA2-associated carcinomas.
|
16541313 |
2006 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Approximately 6% of BRCA1 carriers and 2% of BRCA2 carriers who undergo prophylactic salpingo-oophorectomy will be found to have occult carcinomas if the ovaries and tubes are rigorously examined.
|
16137750 |
2006 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Several other carcinomas seem to be associated with BRCA2 mutations: pancreas, prostate, larynx, gallbladder, bile duct cancer, and malignant melanoma.
|
16982466 |
2006 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.
|
17001151 |
2006 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Current data indicate that each of these histologic subtypes is associated with distinct morphologic and molecular genetic alterations: high-grade serous and possibly endometrioid carcinomas most probably arise from surface epithelial inclusion glands with TP53 mutations and dysfunction of BRCA1 and/or BRCA2; low-grade serous carcinomas probably arise in a stepwise fashion in an adenoma-borderline tumor-carcinoma sequence from typical to micropapillary borderline tumors to low-grade invasive serous carcinoma via activation of the RAS-RAF signaling pathway secondary to mutations in KRAS and BRAF; mucinous carcinomas arise via an adenoma-borderline tumor-carcinoma sequence with mutations in KRAS; low-grade endometrioid carcinomas arise from endometriosis via mutations in CTNNB1 (the gene encoding beta-catenin) and PTEN.
|
15761464 |
2005 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Somatic mutations in the BRCA genes are rarely found in hereditary tumors; by contrast, BRCA1 and BRCA2 loss of heterozygosity (LOH) is found in almost all BRCA1 and BRCA2 carcinomas, respectively.
|
15933754 |
2005 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, most BRCA2-associated carcinomas grouped in a branch composed by ER/PR/BCL2-positive tumors with a higher expression of the cell cycle proteins cyclin D1, cyclin D3, p27, p16, p21, CDK4, CDK2 and CDK1.
|
15770521 |
2005 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that the imaging findings of BRCA1 and BRCA2-associated carcinomas differ from each other and from age-matched cases of sporadic breast carcinoma.
|
15451348 |
2004 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Over 90% of peritoneal cancer in patients from HBOC syndrome kindreds and associated with BRCA1 and BRCA2 mutations are serous carcinomas, which is equivalent with the proportion of ovarian cancers that are serous carcinomas in similar patients.
|
15516851 |
2004 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
No microdeletions, insertions, or point mutations were detected in either RB or BRCA2 in any of the carcinomas.
|
12864795 |
2003 |